FIELD: medicine.
SUBSTANCE: group of inventions refers to an immunobiological agent for bladder cancer treatment on the basis of an adenoviral vector containing a promoter-controlled interferon beta gene, wherein the above adenoviral vector is human adenovirus; the agent additionally contains an enzyme, which provides bladder mucosa secretion splitting. The group of inventions also concerns a method for using the immunobiological agent for bladder cancer treatment involving administering the above immunobiological agent into the bladder.
EFFECT: prolonged action of the immunological agent.
7 cl, 5 ex, 5 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| BCG-BASED IMMUNOBIOLOGICAL MEDICATION FOR URINARY BLADDER CANCER THERAPY AND METHOD FOR THEREOF APPLICATION | 2014 |
|
RU2571822C1 |
| IMMUNOBIOLOGICAL AGENT AND METHOD FOR USE THEREOF TO INDUCE SPECIFIC IMMUNITY AGAINST EBOLA VIRUS | 2015 |
|
RU2578159C1 |
| ONCOLYTIC ADENOVIRUS FOR TREATING CANCER, USING IT, AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2010 |
|
RU2536931C2 |
| METHOD OF PREPARATION OF RECOMBINANT BIRDS VIRUS FOR VACCINATION AND GENETIC THERAPY | 2007 |
|
RU2326942C1 |
| METHODS AND COMPONENTS FOR INDUCTION OF TUMOR- -SPECIFIC CYTOTOXICITY | 1998 |
|
RU2214280C2 |
| IMPROVED VECTOR EXPRESSING TOLL-LIKE RECEPTOR AND AGONIST, AND USE IN CANCER THERAPY | 2014 |
|
RU2682762C2 |
| IMMUNOBIOLOGICAL AGENT AND A METHOD FOR USE THEREOF FOR INDUCING SPECIFIC IMMUNITY TO THE MIDDLE EASTERN RESPIRATORY SYNDROME VIRUS (VERSIONS) | 2018 |
|
RU2709659C1 |
| THERAPEUTIC COMPOSITIONS AND METHODS OF USING FOR TREATING CANCER | 2016 |
|
RU2720984C2 |
| VECTORS CONDITIONALLY EXPRESSING THERAPEUTIC PROTEINS, HOST CELLS COMPRISING THE VECTORS, AND USES THEREOF | 2011 |
|
RU2612788C2 |
| SELF-INACTIVATED HELPER ADENOVIRUSES FOR PREPARING HIGH-CAPACITY RECOMBINANT ADENOVIRUSES | 2009 |
|
RU2520809C2 |
